Dec 01, 2022 / 02:40PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Hello, everyone. Thank you for joining us. Pleasure to have Merck management join us. There's tons to talk about. So I'll be talking at 1.5x speed, but let me turn it over to you guys to kick things off.
Peter Dannenbaum - Merck & Co., Inc. - VP of IR
Umer, thank you very much for having us. Always a pleasure. With me is Dr. Eliav Barr, who is -- this year he has begun to lead our Global Clinical Development at Merck. He's got a long and distinguished career here, most recently Head of Medical Affairs, but also leadership roles in oncology and infectious diseases. And with a cardiologist by training, and I just learned that's why he came to Merck back in the mid-'90s was because of the amazing cardiovascular work we were doing then.
But happy to turn it over to you, right, to get to your questions.
Merck & Co Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot